Company / EPS (Diluted)
NOVAVAX INC EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.41
FY2025
5-year range
-$23.44 / -$5.41
FY2021-FY2025
Trend
+35.7%
vs FY2024
Sector context
#180 of 204
Health Care
What the data says
NOVAVAX INC's eps (diluted) of $-5.41 is lower than 88% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-23.44 in FY2023 to $-0.37 in FY2016.
Based on SEC 10-K filings.
-5.41 in FY2025.
Improved from $-23.44 to $-5.41 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 204This company -$5.41 Sector average -$0.98
▼
-452.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 35.7% year-over-year.
- Ranks #180 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2016.
- Lowest eps (diluted) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.41 | +35.7% |
| FY2024 | -$8.42 | +64.1% |
| FY2023 | -$23.44 | -222.4% |
| FY2022 | -$7.27 | -31.9% |
| FY2021 | -$5.51 | +44.8% |
| FY2020 | -$9.99 | +20.5% |
| FY2019 | -$12.56 | -1119.4% |
| FY2018 | -$1.03 | -71.7% |
| FY2017 | -$0.60 | -62.2% |
| FY2016 | -$0.37 | -19.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026